Chapple CR, Cardozo L, Steers WD, Govier FE. Solifenacin significantly improves all symptoms of overactive bladder syndrome. *Int J Clin Pract* 2006; **60**: 959--66.

Following the publication of the above Review article, the author would like to apologise for the following:

First error, the previous incorrect text (*within section titled* '*Author disclosure*'):

Linda Cardozo, MD, FRCOG, receives money for consultancy and/or advisory work, or research or lecturing from the following companies: Astellas, Lilly/Boehringer Ingelheim, UCB Pharma, Pfizer, Gynecare, Plethora and Cook.

Fred E Govier, MD, has nothing to disclose.

The corrected text:

Linda Cardozo, MD, FRCOG, is an advisor/consultant for Astellas, Lilly/Boehringer Ingelheim, UCB Pharma, Pfizer, Gynecare, Plethora and Cook.

Fred E Govier, MD, is an investigator/consultant for Lilly/Icos, Pfizer, American Medical Systems, Novartis, Astellas and Bayer.

Second error, the previous incorrect text \[*within section titled* '*Introduction*' (*third paragraph*)\]:

There is also increasing evidence that acetylcholine may act on receptors in the suburothelial plexus, thereby influencing the afferent system and detrusor contraction.

The corrected text:

There is also increasing evidence that acetylcholine may act on receptors expressed by the urothelium, suburothelial nerves or interstitial cells, thereby influencing the afferent system and detrusor contraction.

Third error, the previous incorrect text \[*within section titled* '*Methods*, *efficacy analysis*' (*second paragraph*)\]:

A minimally important difference (MID) was defined as a \>5% point change from baseline,

The corrected text:

A minimally important difference (MID) was defined as a ≥5 point change from baseline,

Forth error, in [Table 1](#tbl1){ref-type="table"}, please add '*n* (%)' after the words 'Male' and 'Female' within the 'gender' section.

  --------------------- ---------- ---------- ----------
  Gender                                      
      Male, *n* (%)     219 (19)   121 (22)   242 (21)
      Female, *n* (%)   919 (81)   431 (78)   916 (79)
  --------------------- ---------- ---------- ----------

Fifth error, the previous incorrect text (*within legend to Figure 4*):

‡MIDs based on Reese et al.

The corrected text:

‡MIDs based on Kelleher et al., 2004

Sixth error, the previous incorrect text \[*within section titled* '*Discussion*' (*1st paragraph*)\]:

Therefore, effective treatment of OAB must result in a reduction meaningful to the patient in all of these symptoms.

The corrected text: Therefore, the most efficacious treatment of OAB would ideally result in a reduction meaningful to the patient in all of these symptoms.

Seventh error, the previous incorrect text \[*within section titled* '*Discussion*' (*second paragraph*)\]:

When using the following definition of clinical meaning: MID ≥ 5 percentage point change from baseline;

The corrected text:

When using the following definition of clinical meaning: MID ≥ 5 point change from baseline,

Eighth error, the previous incorrect text (*within section titled* '*Acknowledgements*'):

The analyses in this paper were funded by an educational grant from Astellas. Editorial assistance was provided by Mark Rose, Medicus International.

The corrected text:

Whilst the study was sponsored by an educational grant from Astellas, the views and comments expressed here are those felt appropriate by the authors. Editorial assistance was provided by Mark Rose, Medicus International.

Ninth error, the previous incorrect authors reference 24:

24 Reese PR, Pleil AM, Okano GJ et al.

The corrected authors:

24 Chapple C, Fiala R, Gorilovsky L et al.

Tenth error, the previous incorrect reference 25:

25 Reese PR, Pleil AM, Okano GJ et al. Multinational study of reliability and validity of the King\'s Health Questionnaire in patients with overactive bladder. *Quality of Life Research* 2003; **12**: 427--442.

The corrected reference 25:

25 Kelleher CJ, Pleil AM, Reese PR et al. How much is enough and who says so? The case of the King\'s Health Questionnaire and overactive bladder. *BJOG* 2004; **111**: 605--612.
